In this video interview, Kyle McAllister, co-founder, CEO, Trially, shares real-world examples of AI transforming clinical ...

In this video interview, Kyle McAllister, co-founder, CEO, Trially, explains how staffing reductions caused by clinical trial budget cuts are threatening patient recruitment and retention and warns of ...

Instead, identifying early-stage individuals necessitates biomarker-based screening, which adds layers of complexity to an ...

IntraBio Inc. announced today that it has completed recruitment for its Phase III Pivotal Trial "IB1001-303", Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A randomized, ...

Discover what clinical trials are, why they're vital for new treatments, and how you can participate in life-changing medical ...

Providing a Focused Analysis of Emerging Opportunities, Challenges, and Market Dynamics from 2024 to 2029"Boston, July 02, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, ...

The next frontier in clinical development is modelling feasibility and continuous scenario-planning, even amid changing ...

Smith joins Trially at a pivotal moment. As clinical research sites face mounting enrollment pressure and shrinking pipelines, Trially has emerged as a category-defining technology. In a landscape ...

Patient recruitment remains a significant challenge for biopharma companies, often leading to delays and increased costs in clinical trials. Traditional recruitment methods can be time-consuming ...

Pfizer's recent trial termination makes it yet another company facing challenges with CD47 studies in oncology.

The clinical trial support services market is experiencing significant growth, driven by the increasing incidence of chronic illnesses such as cancer ...

Pfizer insists that the discontinuation of the Phase II study was due to recruitment difficulties and was not linked to ...